9 results on '"Rejto, Paul A."'
Search Results
2. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
- Author
-
Zhong, Wenyan, Myers, Jeremy S., Wang, Fang, Wang, Kai, Lucas, Justin, Rosfjord, Edward, Lucas, Judy, Hooper, Andrea T., Yang, Sharon, Lemon, Lu Anna, Guffroy, Magali, May, Chad, Bienkowska, Jadwiga R., and Rejto, Paul A.
- Published
- 2020
- Full Text
- View/download PDF
3. TNER: a novel background error suppression method for mutation detection in circulating tumor DNA.
- Author
-
Shibing Deng, Donghui Huang, Kai Wang, Valdez, Crystal, Kinong, Jennifer, Rejto, Paul A., Bienkowska, Jadwiga, Hardwick, James, and Tao Xie
- Subjects
CIRCULATING tumor DNA ,GENETIC mutation ,DISEASE progression ,ERRORS ,EARLY detection of cancer - Abstract
Background: Ultra-deep next-generation sequencing of circulating tumor DNA (ctDNA) holds great promise as a tool for the early detection of cancer and for monitoring disease progression and therapeutic responses. However, the low abundance of ctDNA in the bloodstream coupled with technical errors introduced during library construction and sequencing complicates mutation detection. Results: To achieve high accuracy of variant calling via better distinguishing low-frequency ctDNA mutations from background errors, we introduce TNER (Tri-Nucleotide Error Reducer), a novel background error suppression method that provides a robust estimation of background noise to reduce sequencing errors. The results on both simulated data and real data from healthy subjects demonstrate that the proposed algorithm consistently outperforms a current, state-of-the-art, position-specific error polishing model, particularly when the sample size of healthy subjects is small. Conclusions: TNER significantly enhances the specificity of downstream ctDNA mutation detection without sacrificing sensitivity. The tool is publicly available at https://github.com/ctDNA/TNER. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
- Author
-
Zhou Zhu, Ihle, Nathan T., Rejto, Paul A., and Zarrinkar, Patrick P.
- Subjects
FUNCTIONAL genomics ,ONCOLOGY ,GENOMES ,GENOMICS ,CELL lines ,FATE mapping (Genetics) - Abstract
Background: Genome-scale functional genomic screens across large cell line panels provide a rich resource for discovering tumor vulnerabilities that can lead to the next generation of targeted therapies. Their data analysis typically has focused on identifying genes whose knockdown enhances response in various pre-defined genetic contexts, which are limited by biological complexities as well as the incompleteness of our knowledge. We thus introduce a complementary data mining strategy to identify genes with exceptional sensitivity in subsets, or outlier groups, of cell lines, allowing an unbiased analysis without any a priori assumption about the underlying biology of dependency. Results: Genes with outlier features are strongly and specifically enriched with those known to be associated with cancer and relevant biological processes, despite no a priori knowledge being used to drive the analysis. Identification of exceptional responders (outliers) may not lead only to new candidates for therapeutic intervention, but also tumor indications and response biomarkers for companion precision medicine strategies. Several tumor suppressors have an outlier sensitivity pattern, supporting and generalizing the notion that tumor suppressors can play context-dependent oncogenic roles. Conclusions: The novel application of outlier analysis described here demonstrates a systematic and data-driven analytical strategy to decipher large-scale functional genomic data for oncology target and precision medicine discoveries. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding.
- Author
-
Zhu, Zhou, Shi, Manli, Hu, Wenyue, Estrella, Heather, Engebretsen, Jon, Nichols, Tim, Briere, David, Hosea, Natilie, Los, Gerrit, Rejto, Paul A., and Fanjul, Andrea
- Subjects
DOSAGE forms of drugs ,ANDROGENS ,RADIOLIGAND assay ,PROSTATE cancer ,CHROMATIN - Abstract
Background: The androgen receptor plays a critical role throughout the progression of prostate cancer and is an important drug target for this disease. While chromatin immunoprecipitation coupled with massively parallel sequencing (ChIP-Seq) is becoming an essential tool for studying transcription and chromatin modification factors,it has rarely been employed in the context of drug discovery.Results: Here we report changes in the genome-wide AR binding landscape due to dose-dependent inhibition by drug-like small molecules using ChIP-Seq. Integration of sequence analysis, transcriptome profiling, cell viability assays and xenograft tumor growth inhibition studies enabled us to establish a direct cistrome-activity relationship for two novel potent AR antagonists. By selectively occupying the strongest binding sites, AR signaling remains active even when androgen levels are low, as is characteristic of first-line androgen ablation therapy. Coupled cistrome and transcriptome profiling upon small molecule antagonism led to the identification of a core set of AR direct effector genes that are most likely to mediate the activities of targeted agents: unbiased pathway mapping revealed that AR is a key modulator of steroid metabolism by forming a tightly controlled feedback loop with other nuclear receptor family members and this oncogenic effect can be relieved by antagonist treatment. Furthermore,we found that AR also has an extensive role in negative gene regulation, with estrogen (related) receptor likely mediating its function as a transcriptional repressor.Conclusions: Our study provides a global and dynamic view of AR’s regulatory program upon antagonism, which may serve as a molecular basis for deciphering and developing AR therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Statistical method on nonrandom clustering with application to somatic mutations in cancer.
- Author
-
Jingjing Ye, Pavlicek, Adam, Lunney, Elizabeth A, Rejto, Paul A, and Chi-Hse Teng
- Subjects
CANCER genetics ,AMINO acids ,AMINO acid sequence ,TUMOR suppressor genes ,GENETICS ,ONCOGENES - Abstract
Background: Human cancer is caused by the accumulation of tumor-specific mutations in oncogenes and tumor suppressors that confer a selective growth advantage to cells. As a consequence of genomic instability and high levels of proliferation, many passenger mutations that do not contribute to the cancer phenotype arise alongside mutations that drive oncogenesis. While several approaches have been developed to separate driver mutations from passengers, few approaches can specifically identify activating driver mutations in oncogenes, which are more amenable for pharmacological intervention. Results: We propose a new statistical method for detecting activating mutations in cancer by identifying nonrandom clusters of amino acid mutations in protein sequences. A probability model is derived using order statistics assuming that the location of amino acid mutations on a protein follows a uniform distribution. Our statistical measure is the differences between pair-wise order statistics, which is equivalent to the size of an amino acid mutation cluster, and the probabilities are derived from exact and approximate distributions of the statistical measure. Using data in the Catalog of Somatic Mutations in Cancer (COSMIC) database, we have demonstrated that our method detects well-known clusters of activating mutations in KRAS, BRAF, PI3K, and β-catenin. The method can also identify new cancer targets as well as gain-of-function mutations in tumor suppressors. Conclusions: Our proposed method is useful to discover activating driver mutations in cancer by identifying nonrandom clusters of somatic amino acid mutations in protein sequences. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
7. TNER: a novel background error suppression method for mutation detection in circulating tumor DNA.
- Author
-
Deng S, Lira M, Huang D, Wang K, Valdez C, Kinong J, Rejto PA, Bienkowska J, Hardwick J, and Xie T
- Subjects
- Computer Simulation, High-Throughput Nucleotide Sequencing, Humans, Neoplasms genetics, Normal Distribution, ROC Curve, Software, Circulating Tumor DNA genetics, DNA Mutational Analysis methods, Mutation genetics
- Abstract
Background: Ultra-deep next-generation sequencing of circulating tumor DNA (ctDNA) holds great promise as a tool for the early detection of cancer and for monitoring disease progression and therapeutic responses. However, the low abundance of ctDNA in the bloodstream coupled with technical errors introduced during library construction and sequencing complicates mutation detection., Results: To achieve high accuracy of variant calling via better distinguishing low-frequency ctDNA mutations from background errors, we introduce TNER (Tri-Nucleotide Error Reducer), a novel background error suppression method that provides a robust estimation of background noise to reduce sequencing errors. The results on both simulated data and real data from healthy subjects demonstrate that the proposed algorithm consistently outperforms a current, state-of-the-art, position-specific error polishing model, particularly when the sample size of healthy subjects is small., Conclusions: TNER significantly enhances the specificity of downstream ctDNA mutation detection without sacrificing sensitivity. The tool is publicly available at https://github.com/ctDNA/TNER .
- Published
- 2018
- Full Text
- View/download PDF
8. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
- Author
-
Zhu Z, Ihle NT, Rejto PA, and Zarrinkar PP
- Subjects
- Cell Line, Tumor, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic metabolism, Computational Biology methods, Drug Discovery, Gene Expression Profiling, High-Throughput Nucleotide Sequencing, Humans, Molecular Targeted Therapy, Neoplasms drug therapy, Neoplasms metabolism, Signal Transduction drug effects, Biomarkers, Tumor, Genome, Human, Genomics methods, Neoplasms genetics, Precision Medicine methods
- Abstract
Background: Genome-scale functional genomic screens across large cell line panels provide a rich resource for discovering tumor vulnerabilities that can lead to the next generation of targeted therapies. Their data analysis typically has focused on identifying genes whose knockdown enhances response in various pre-defined genetic contexts, which are limited by biological complexities as well as the incompleteness of our knowledge. We thus introduce a complementary data mining strategy to identify genes with exceptional sensitivity in subsets, or outlier groups, of cell lines, allowing an unbiased analysis without any a priori assumption about the underlying biology of dependency., Results: Genes with outlier features are strongly and specifically enriched with those known to be associated with cancer and relevant biological processes, despite no a priori knowledge being used to drive the analysis. Identification of exceptional responders (outliers) may not lead only to new candidates for therapeutic intervention, but also tumor indications and response biomarkers for companion precision medicine strategies. Several tumor suppressors have an outlier sensitivity pattern, supporting and generalizing the notion that tumor suppressors can play context-dependent oncogenic roles., Conclusions: The novel application of outlier analysis described here demonstrates a systematic and data-driven analytical strategy to decipher large-scale functional genomic data for oncology target and precision medicine discoveries.
- Published
- 2016
- Full Text
- View/download PDF
9. Statistical method on nonrandom clustering with application to somatic mutations in cancer.
- Author
-
Ye J, Pavlicek A, Lunney EA, Rejto PA, and Teng CH
- Subjects
- Genes, ras genetics, Genome, Human, Humans, Proto-Oncogene Proteins B-raf genetics, beta Catenin genetics, Cluster Analysis, Models, Statistical, Mutation, Neoplasms genetics
- Abstract
Background: Human cancer is caused by the accumulation of tumor-specific mutations in oncogenes and tumor suppressors that confer a selective growth advantage to cells. As a consequence of genomic instability and high levels of proliferation, many passenger mutations that do not contribute to the cancer phenotype arise alongside mutations that drive oncogenesis. While several approaches have been developed to separate driver mutations from passengers, few approaches can specifically identify activating driver mutations in oncogenes, which are more amenable for pharmacological intervention., Results: We propose a new statistical method for detecting activating mutations in cancer by identifying nonrandom clusters of amino acid mutations in protein sequences. A probability model is derived using order statistics assuming that the location of amino acid mutations on a protein follows a uniform distribution. Our statistical measure is the differences between pair-wise order statistics, which is equivalent to the size of an amino acid mutation cluster, and the probabilities are derived from exact and approximate distributions of the statistical measure. Using data in the Catalog of Somatic Mutations in Cancer (COSMIC) database, we have demonstrated that our method detects well-known clusters of activating mutations in KRAS, BRAF, PI3K, and beta-catenin. The method can also identify new cancer targets as well as gain-of-function mutations in tumor suppressors., Conclusions: Our proposed method is useful to discover activating driver mutations in cancer by identifying nonrandom clusters of somatic amino acid mutations in protein sequences.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.